Mar. 27 at 12:00 PM
$TLSI
TriSalus Life Sciences reported strong financial results for Q4 and full-year 2024, with revenues reaching
$8.3 million in Q4 and
$29.4 million for the full year, showing growth of 44% and 59% respectively versus prior year periods.
The company maintained impressive gross margins of 85% in Q4 and 86% for 2024.
Key developments include the launch of TriNav LV Infusion System and TriGuide Guiding Catheter for larger vessels, expanding their addressable market to
$375 million.
The company completed enrollment in the PERIO-03 Phase 1 trial for pancreatic cancer, with final data expected mid-2025.
For 2025, TriSalus reaffirmed guidance projecting over 50% revenue growth, more than 20% reduction in operating expenses, positive EBITDA, and positive cash flow in H2 2025.
The company ended 2024 with
$8.5 million in cash and expects sufficient runway throughout 2025.
